Evidence map›Paper›PMID 40859815›Full record

ArticleBritish journal of haematology2025

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

Antonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, José Luis López-Lorenzo, Javier Cornago, Pilar Llamas, Manuel Fresno, Javier Santos, María Villa-Morales

Abstract read
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonio LaheraDepartment of Molecular Biology, Universidad Autónoma de Madrid, Madrid, Spain.
Laura Vela-MartínCentro de Biologia Molecular Severo Ochoa (CBM), CSIC-Universidad Autonoma de Madrid, Madrid, Spain.
Pablo Fernández-NavarroUnit of Cancer and Environmental Epidemiology, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
José Luis López-LorenzoDivision of Hematology and Hemotherapy, IIS Fundación Jiménez Díaz, Madrid, Spain.
Javier CornagoDivision of Hematology and Hemotherapy, IIS Fundación Jiménez Díaz, Madrid, Spain.
Pilar LlamasDivision of Hematology and Hemotherapy, IIS Fundación Jiménez Díaz, Madrid, Spain.
Manuel FresnoDepartment of Molecular Biology, Universidad Autónoma de Madrid, Madrid, Spain.
Javier SantosCentro de Biologia Molecular Severo Ochoa (CBM), CSIC-Universidad Autonoma de Madrid, Madrid, Spain.
María Villa-MoralesCentro de Biologia Molecular Severo Ochoa (CBM), CSIC-Universidad Autonoma de Madrid, Madrid, Spain.ORCID https://orcid.org/0000-0001-7906-0169

Funding

Instituto de Investigación Sanitaria Fundación Jiménez DíazMinisterio de Ciencia e Innovación PID2022-137487OB-I00Ministerio de Ciencia, Innovación y Universidades RTI2018-093330-B-I00Ministerio de Economía y Competitividad SAF2015-70561-R
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse outcomechildhood leukaemiaprognostic factorsT‐cell acute lymphoblastic leukaemia (T‐ALL)transcriptional signature

Identifiers

PMID40859815
PMCPMC12624190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.